Market Overview

UPDATE: Stifel Nicolaus Initiates Abbott Laboratories at Buy Post Spin

Related ABT
Benzinga's M&A Chatter for Thursday August 27, 2015
Benzinga's Volume Movers
XOMA Shoots up on Immuno-Oncology Deal with Novartis (Zacks)

Stifel Nicolaus initiated Abbott Laboratories (NYSE: ABT) with a Buy rating and a $40.00 price target.

Stifel Nicolaus commented, "Post-spin, we believe Abbott is now a balanced, diversified medical products company with an attractive, long-term outlook for mid-to-upper single-digit sales growth and low double-digit EPS growth. Although ABT currently trades at a premium to its peers, we see potential for further EPS upside over time, driven by an intensified focus on growth and margin enhancing initiatives. Using a sum-of-the-parts valuation framework, we arrive at a $40 target price."

Abbott Laboratories closed at $34.46 on Thursday.

Latest Ratings for ABT

Aug 2015Credit SuisseAssumesOutperform
Aug 2015JefferiesMaintainsHold
Jul 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Analyst Ratings


Related Articles (ABT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters